z-logo
open-access-imgOpen Access
Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy
Author(s) -
Claudia Tersteeg,
Steven de Maat,
Simon F. De Meyer,
Michel W.J. Smeets,
Arjan D. Barendrecht,
Mark Roest,
Gerard Pasterkamp,
Rob Fijnheer,
Karen Vanhoorelbeke,
Philip G. de Groot,
Coen Maas
Publication year - 2014
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.113.006727
Subject(s) - adamts13 , thrombotic microangiopathy , von willebrand factor , plasmin , thrombotic thrombocytopenic purpura , medicine , platelet , plasminogen activator , immunology , biochemistry , enzyme , chemistry , disease
Von Willebrand factor (VWF) multimer size is controlled through continuous proteolysis by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type I motif, member 13). This prevents spontaneous platelet agglutination and microvascular obstructions. ADAMTS13 deficiency is associated with thrombotic thrombocytopenic purpura, in which life-threatening episodes of microangiopathy damage kidneys, heart, and brain. Enigmatically, a complete ADAMTS13 deficiency does not lead to continuous microangiopathy. We hypothesized that plasmin, the key enzyme of the fibrinolytic system, serves as a physiological backup enzyme for ADAMTS13 in the degradation of pathological platelet-VWF complexes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom